These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1243 related items for PubMed ID: 11426523

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC.
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [Abstract] [Full Text] [Related]

  • 3. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
    Pedersen-Bjergaard J, Pedersen M, Myhre J, Geisler C.
    Leukemia; 1997 Oct; 11(10):1654-60. PubMed ID: 9324285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE.
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [Abstract] [Full Text] [Related]

  • 7. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors.
    Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A, Fung H, Bhatia R, Kashyap A, Molina A, O'Donnell MR, Parker PA, Sniecinski I, Snyder DS, Spielberger R, Stein A, Forman SJ.
    Blood; 2000 Mar 01; 95(5):1588-93. PubMed ID: 10688812
    [Abstract] [Full Text] [Related]

  • 8. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
    Horning SJ, Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG.
    J Clin Oncol; 1994 Dec 01; 12(12):2552-8. PubMed ID: 7989928
    [Abstract] [Full Text] [Related]

  • 9. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 Sep 15; 21(18):3440-6. PubMed ID: 12668650
    [Abstract] [Full Text] [Related]

  • 10. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
    Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG.
    Ann Oncol; 1991 Jan 15; 2 Suppl 1():47-50. PubMed ID: 2043498
    [Abstract] [Full Text] [Related]

  • 11. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
    Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR.
    J Clin Oncol; 1994 Dec 15; 12(12):2527-34. PubMed ID: 7989926
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
    J Clin Oncol; 1994 Oct 15; 12(10):2176-86. PubMed ID: 7523609
    [Abstract] [Full Text] [Related]

  • 14. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM, Le Beau MM, Anastasi J, Williams SF.
    Bone Marrow Transplant; 1999 Jun 15; 23(11):1161-5. PubMed ID: 10382956
    [Abstract] [Full Text] [Related]

  • 15. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P, Stein A, Smith E, Planas I, Kashyap A, Spielberger R, Fung H, Krishnan A, Bhatia R, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Slovak M, Niland JC, Forman SJ.
    Clin Lymphoma; 2000 Jun 15; 1(1):46-54. PubMed ID: 11707813
    [Abstract] [Full Text] [Related]

  • 16. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
    Alvarnas JC, Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ.
    Biol Blood Marrow Transplant; 2000 Jun 15; 6(3A):352-8. PubMed ID: 10905773
    [Abstract] [Full Text] [Related]

  • 17. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Robertson MJ, Abonour R, Hromas R, Nelson RP, Fineberg NS, Cornetta K.
    Leuk Lymphoma; 2005 Oct 15; 46(10):1477-87. PubMed ID: 16194894
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
    Berglund A, Enblad G, Carlson K, Glimelius B, Hagberg H.
    Eur J Haematol; 2000 Jul 15; 65(1):17-22. PubMed ID: 10914935
    [Abstract] [Full Text] [Related]

  • 19. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G.
    Blood; 1995 Mar 01; 85(5):1381-90. PubMed ID: 7858268
    [Abstract] [Full Text] [Related]

  • 20. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
    Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL, Miller KB.
    J Clin Oncol; 1994 Nov 01; 12(11):2423-31. PubMed ID: 7964959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.